drugset / Trial / NCT02366949
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
RandomizedParallel-groupOpen-labelTreatment
Summary
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5 days off) in subjects with advanced malignancies.
Timeline
- Start
- 2015-02-27
- Primary completion
- 2018-03-30
- Completion
- 2019-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY1217389 | Small molecule | 0.25 mg | Oral |
| Subject | Paclitaxel | Small molecule | 90 mg/m2 | Intravenous |
Indications
No indication recorded.